Search results
focus on five domains: (1) management of general and organ- specific SLE, (2) targets of treatment, (3) tapering/withdrawal of treatment, (4) management of patients with SLE and anti-phospholipid syndrome (APS), and (5) the efficacy and safety of vaccination against herpes zoster and SARS-CoV2 viruses (a
22 maj 2023 · Bullous systemic lupus erythematosus (BSLE) is a rare manifestation of systemic lupus erythematosus. It has clinical and histological features that may lead to misdiagnosis and delayed treatment of this easily treatable condition.
1 wrz 2021 · Empirical and “off-label” application of topical and systemic medications are still common in treatment for CLE. In 2017, a guideline for treatment of CLE has been developed by the European Dermatology Forum in cooperation with the European Academy of Dermatology and Venereology (EADV) [1].
Bullous systemic lupus erythematosus (BSLE) is an uncommon blistering eruption that can occur in patients with systemic lupus erythematosus (SLE). Between 59 and. 85 % of SLE patients will have skin manifestations of their disease, but less than 5 % will develop bullous disease [1–3].
31 paź 2014 · Bullous systemic lupus erythematosus (BSLE) is an uncommon blistering eruption that can occur in patients with systemic lupus erythematosus (SLE). Between 59 and 85 % of SLE patients will have skin manifestations of their disease, but less than 5 % will develop bullous disease [ 1 – 3 ].
8 lis 2023 · Bullous SLE is rare blistering disorder characterized by subepidermal blisters. We, hereby, present a case of bullous SLE in a 24-year-old female who responded well to systemic glucocorticoids, mycophenolate mofetil, and dapsone.
Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus erythematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
